B
Bruno François
Researcher at French Institute of Health and Medical Research
Publications - 223
Citations - 14166
Bruno François is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Intensive care unit & Intensive care. The author has an hindex of 47, co-authored 197 publications receiving 11525 citations. Previous affiliations of Bruno François include University of Limoges.
Papers
More filters
Journal ArticleDOI
Effect of Treatment With Low Doses of Hydrocortisone and Fludrocortisone on Mortality in Patients With Septic Shock
Djillali Annane,Véronique Sébille,C. Charpentier,Pierre-Edouard Bollaert,Bruno François,Jean-Michel Korach,Gilles Capellier,Yves Cohen,Elie Azoulay,Gilles Troché,Philippe Chaumet-Riffaut,Eric Bellissant +11 more
TL;DR: In this trial, a 7-day treatment with low doses of hydrocortisone and fludrocort isone significantly reduced the risk of death in patients with septic shock and relative adrenal insufficiency without increasing adverse events.
Journal ArticleDOI
Assessment of the worldwide burden of critical illness: The Intensive Care Over Nations (ICON) audit
Jean Louis Vincent,John C. Marshall,Silvio A. Ñamendys-Silva,Bruno François,Ignacio Martin-Loeches,Jeffrey Lipman,Konrad Reinhart,Massimo Antonelli,Peter Pickkers,Hassane Njimi,Edgar Jimenez,Yasser Sakr +11 more
TL;DR: In this article, the authors did an international audit of ICU patients worldwide and assessed variations between hospitals and countries in terms of the ICU mortality, showing that sepsis remains a major health problem worldwide, associated with high mortality rates in all countries.
Journal ArticleDOI
Drotrecogin Alfa (Activated) for Adults with Severe Sepsis and a Low Risk of Death
Edward Abraham,Pierre-François Laterre,Rekha Garg,Howard Levy,Deepak Talwar,Benjamin L. Trzaskoma,Bruno François,Jeffrey S. Guy,Martina Brückmann,Álvaro Réa-Neto,Rolf Rossaint,Dominique Perrotin,Armin Sablotzki,Nancy Arkins,Barbara G. Utterback,William L. Macias +15 more
TL;DR: The absence of a beneficial treatment effect, coupled with an increased incidence of serious bleeding complications, indicates that DrotAA should not be used in patients with severe sepsis who are at low risk for death, such as those with single-organ failure or an APACHE II score less than 25.
Journal ArticleDOI
Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial.
Steven M. Opal,Pierre-François Laterre,Bruno François,Steven P. LaRosa,Derek C. Angus,Jean-Paul Mira,Xavier Wittebole,Thierry Dugernier,Dominique Perrotin,Mark Tidswell,Luis Jauregui,Kenneth Krell,Jan Pachl,Takahashi Takeshi,Claus Peckelsen,Edward Cordasco,Chia-Sheng Chang,Sandra Oeyen,Naoki Aikawa,Tatsuya Maruyama,Roland M. H. Schein,Andre C. Kalil,Marc Van Nuffelen,Melvyn Lynn,Daniel P. Rossignol,Jagadish Gogate,Mary B. Roberts,Mary B. Roberts,Janice L. Wheeler,Jean Louis Vincent +29 more
TL;DR: Among patients with severe sepsis, the use of eritoran, compared with placebo, did not result in reduced 28-day mortality, and no significant differences were observed in any of the prespecified subgroups.
Journal ArticleDOI
Hydrocortisone plus Fludrocortisone for Adults with Septic Shock
Djillali Annane,Alain Renault,Christian Brun-Buisson,Bruno Mégarbane,Jean-Pierre Quenot,Shidasp Siami,Alain Cariou,Xavier Forceville,Carole Schwebel,Claude Martin,Jean-François Timsit,Benoit Misset,Mohamed Ali Benali,Gwenhael Colin,Bertrand Souweine,Karim Asehnoune,Emmanuelle Mercier,Loïc Chimot,C. Charpentier,Bruno François,Thierry Boulain,Franck Petitpas,Jean-Michel Constantin,Gilles Dhonneur,François Baudin,Alain Combes,Julien Bohé,Jean-François Loriferne,Roland Amathieu,Fabrice Cook,Michel Slama,Olivier Leroy,Gilles Capellier,Auguste Dargent,Tarik Hissem,Virginie Maxime,Eric Bellissant +36 more
TL;DR: In this trial involving patients with septic shock, 90‐day all‐cause mortality was lower among those who received hydrocortisone plus fludrocort isone or with drotrecogin alfa (activated), the combination of the three drugs, or their respective placebos.